NasdaqGS - Nasdaq Real Time Price USD

MacroGenics, Inc. (MGNX)

1.5200

-0.0500

(-3.18%)

As of 11:32:39 AM EDT. Market Open.

Earnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50

MacroGenics, Inc. ( NASDAQ:MGNX ) defied analyst predictions to release its first-quarter results, which were ahead of...

Simply Wall St. 5 days ago

MGNX
-3.18%
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -6.56% and 5.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 days ago

MGNX
-3.18%
MacroGenics: Q1 Earnings Snapshot

ROCKVILLE, Md. AP) — MacroGenics Inc. MGNX) on Tuesday reported a loss of $41 million in its first quarter.

Associated Press Finance 7 days ago

MGNX
-3.18%
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWI

GlobeNewswire 7 days ago

MGNX
-3.18%
MacroGenics Announces Date of First Quarter 2025 Financial Results

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025. The Company will not be hosting a conference call to discuss its financial results or corporate progress f

GlobeNewswire 14 days ago

MGNX
-3.18%
MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month: The Citizens Life Sciences Conference (New York). Members of MacroGenics’ management team will participate in a fireside cha

GlobeNewswire 19 days ago

MGNX
-3.18%
4 Medical Product Stocks to Buy From a Challenging Industry

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.

Zacks last month

PODD

MGNX
-3.18%

CLRB
908 Devices Leads These 3 Penny Stocks To Consider

In an extraordinary turn of events, the U.S. stock market experienced a significant surge as major indices like the Dow Jones and Nasdaq posted some of their best performances in years, following a temporary pause on tariffs by President Trump. Amidst this backdrop, investors are exploring various avenues for potential returns, including penny stocks—a term that may seem outdated but continues to represent opportunities in smaller or newer companies. Despite their reputation for volatility,...

Simply Wall St. last month

CRBU

MASS

MGNX
-3.18%
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for MacroGenics (MGNX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks last month

MGNX
-3.18%
MacroGenics axes ADC drug following Phase II failure in prostate cancer

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

Clinical Trials Arena last month

MGNX
-3.18%

GLDAF
Q4 2024 MacroGenics Inc Earnings Call

Q4 2024 MacroGenics Inc Earnings Call

Thomson Reuters StreetEvents last month

MGNX
-3.18%
Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses

Macrogenics Inc (MGNX) reports a significant revenue increase driven by collaborative agreements, despite a widened net loss and increased R&D expenses.

GuruFocus.com last month

MGNX
-3.18%
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript

MGNX earnings call for the period ending December 31, 2024.

Motley Fool last month

MGNX
-3.18%
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for MacroGenics (MGNX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks last month

MGNX
-3.18%
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -8.70% and 57.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

MGNX
-3.18%
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway e

GlobeNewswire last month

MGNX
-3.18%
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent co

GlobeNewswire 2 months ago

MGNX
-3.18%
MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March: TD Cowen 45th Annual Healthcare Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will partici

GlobeNewswire 2 months ago

MGNX
-3.18%
Discovering US Penny Stocks In February 2025

The U.S. stock market recently experienced a significant downturn, with major indices like the Dow Jones and Nasdaq Composite suffering their largest weekly losses in months. Amid this broader market volatility, investors may find themselves exploring alternative avenues for growth, such as penny stocks. Although often associated with smaller or newer companies, penny stocks can still offer substantial opportunities when backed by strong financials and solid fundamentals. In this article, we...

Simply Wall St. 2 months ago

OSS

MGNX
-3.18%
The past year for MacroGenics (NASDAQ:MGNX) investors has not been profitable

Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning...

Simply Wall St. 3 months ago

MGNX
-3.18%

Performance Overview

Return	MGNX	S&P 500 (^GSPC)
YTD	-53.23%	+0.78%
1-Year	-64.32%	+11.39%
3-Year	-61.81%	+51.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MacroGenics, Inc. (MGNX)

Earnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

MacroGenics: Q1 Earnings Snapshot

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

MacroGenics Announces Date of First Quarter 2025 Financial Results

MacroGenics to Participate in Upcoming Investor Conference

4 Medical Product Stocks to Buy From a Challenging Industry

908 Devices Leads These 3 Penny Stocks To Consider

MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MacroGenics axes ADC drug following Phase II failure in prostate cancer

Q4 2024 MacroGenics Inc Earnings Call

Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses

MacroGenics (MGNX) Q4 2024 Earnings Call Transcript

MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

MacroGenics to Participate in Upcoming Investor Conferences

Discovering US Penny Stocks In February 2025

The past year for MacroGenics (NASDAQ:MGNX) investors has not been profitable

Performance Overview